Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
April 2015

Antidepressants and the Risk of a Manic Switch in Young Bipolar Patients
Current evidence suggests that antidepressants are associated with a substantially increased risk of precipitating a manic switch in children and adolescents with bipolar disorder.

Start Lithium Early?
Starting lithium early in the course of bipolar disorder appears to improve the probability of an excellent response to lithium.

New-Onset Cardiovascular Disease in Bipolar Disorder Patients
Patients with bipolar I or bipolar II disorder experience cardiovascular disease earlier in their lives and at a higher rate than the general population and than patients with major depressive disorder.

In Brief
Attention-Deficit/Hyperactivity Disorder (ADHD) Is Associated with Increased Mortality; Depressive, Anxiety, and Behavioral Disorders May Be Risk Factors for Bipolar Disorder

Antipsychotics and Mortality in Schizophrenia
Examining a nationwide cohort of patients with schizophrenia, investigators in Finland found that the highest risk of mortality was associated with no antipsychotic treatment, and the next highest risk came from high antipsychotic doses.

Anticholinergic Drugs for Dementia Patients
A majority of nursing home residents with dementia are treated with anticholinergic agents, which may counteract the benefits of acetylcholinesterase inhibitors and directly impair memory and cognition.

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.